%PDF-1.4
%
1 0 obj
<>stream
iText 4.2.0 by 1T3XTCheckMate 141 study,Cost-effectiveness,Nivolumab,Quality-adjusted life-years,Recurrent/metastatic,Sensitivity analyses,Squamous cell carcinoma of the head and neck,Treatment options2016-03-16T18:02:50+05:30Arbortext Advanced Print Publisher 9.1.406/W2020-01-13T13:18:41-08:002020-01-13T13:18:41-08:00uuid:8addd02c-2a8d-4824-a074-0375b52bef83uuid:9735c38c-787b-4f5b-aca7-e8422204bc96journalJournal of Medical Economics© 2020 Informa UK Limited, trading as Taylor & Francis Group1369-69981941-837X00-00000010.1080/13696998.2020.1715414http://dx.doi.org/10.1080/13696998.2020.1715414application/pdf10.1080/13696998.2020.1715414enCost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United StatesTaylor & FrancisJournal of Medical Economics, 2020. doi: 10.1080/13696998.2020.1715414Haddad RobertCohen Ezra E.W.Venkatachalam MeenaYoung KateSingh PriankaShaw James W.Korytowsky BeataAbraham PranavHarrington Kevin J.CheckMate 141 studyCost-effectivenessNivolumabQuality-adjusted life-yearsRecurrent/metastaticSensitivity analysesSquamous cell carcinoma of the head and neckTreatment optionsAM2020-01-13truewww.tandfonline.com10.1080/13696998.2020.1715414www.tandfonline.comtrue2020-01-1310.1080/13696998.2020.1715414
endstream
endobj
4 0 obj
<>stream
xn\_~ 4;V 9l9X K~U$"9Q鱹ԫ}`O*O_e&,9$x..OK]~ǡ.K\5އZ-kֺÒꂫ3Z]ڪ+C{u^o= yf|;~?U`~>/Olqe+6
-(D=>K{@16fo^ʙi~
-[߲G%(_aT _y:C0i8z{:}ҁIM9Y]ǂ]|q ֚EN}#۟iO=?Mc'klh!O>#d7:SrF..ʤ3,S3w`aDWoe
1ʜაwq턐bJ<ȶ&kWɐ $p
~pXvn)[ܝC_ArYq3d<5b3쉤ō,$AڠHh{/VzbJMпLsP rAc{?"8W$آ.%םl~ 8Tik85&@OrñoM*bydգ;ITc]0UYO#rȭjg_VS64T_uE!s61j|pkTX=c6N:}A
6ďN)ph[lE^5.ڥX2MyMwry5?quVuuˡq6{`%&6^
A4fQ[]y0]DEQ i
$g2G(x#Zt+gV);ï2Aer
<@s{sds ulm50b(Z:@V匴 LgaȉCs
EnSLw
%Iܑ^l9{Usx=Lj1,b Bko&zuvnBf{;DʩOG}UD*3p
>77ho Q??Vi$e-NuIp( X*tP}2*c]il͖>Vo1sWk8uܬS[;kMrkkNif|f]Қ/w.eyo
CYMɘB~Qj)X^Tec2
$[X`rBGG慣Q䪬W aE*V슠}؛JMW{d}S==".2:BqWh#DXjD}W
Zo൶g qz1?4r.o`yko.N`Fa$F"|TRYnxځ79`VKQ}_ZklGF xnւ7G
1aM)"b